Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Chighizola, Cecilia ^a   Meroni, Pier Luigi ^a   Schreiber, Benjamin E ^b   Coghlan, John G ^b   Denton, Christopher P ^b   Ong, Voon H ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cardiac involvement; N TproBNP; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIFFUSE SCLERODERMA; DISEASE DURATION; FEMALE; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIMITED SCLERODERMA; LUNG ARTERY PRESSURE; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LONDON; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84867342807     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kahan A, Allanore Y: Primary myocardial involvement in systemic sclerosis. Rheumatology 2006; 45: 14-17.
2. Perera A, Fertig N, Lucas M et al.: Clinical subsets, skin thickening progression rate, and serum antibody levels in systemic sclerosis with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-2746.
3. Meune C, Vignaux O, Kahan A, Allanore Y: Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010; 103: 46-52.
4. Champion HC: The heart in scleroderma. Rheum Dis Clin North Am 2008; 34: 181-188.
5. Czirják L, Kumánovics G, Varjú C et al.: Survival and causes of death in 366 hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
6. Vachiéry JL, Coghlan G: Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-169.
7. Hachulla AL, Launay D, Gaxotte V et al.: Cardiac magnetic resonance imaging in systemic sclerosis: a cross sectional observational study of 52 patients. Ann Rheum Dis 2009; 68: 1878-1884.
8. Wilkins MR, Redondo J, Brown L: The natriuretic-peptide family. Lancet 1997; 349: 1307-1310.
9. Hall C: Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 257-260.
10. Williams MH, Handler CE, Akram R et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hyperthension. Eur Heart J 2006; 27: 1485-1494.
11. Leroy EC, Black C, Fleischmajer R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998; 15: 202-205.
12. Allanore Y, Wahbi K, Borderie D et al.: N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009; 68: 1885-1889.
13. Allanore Y, Meune C: N-terminal probrain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009; 27 (Suppl. 54): S59-S63.
14. Jarai R, Kaun C, Weiss TW et al.: Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factorbeta. J Cell Mol Med 2009; 13: 4415-4421.
15. Huntley BK, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC: B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J Cell Physiol 2010; 225: 251-255.
16. Januzzi JL: The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use. Arch Cardiovasc Dis 2012; 105: 40-50.